Survey
Quarterly Survey: PSMA PET Imaging Agents Trends & Preferences October 2025
Ticker(s): LNTH, NVSSurvey results include 20 physicians involved in the diagnosing and treating of prostate cancer.
How many mCRPC patients do you see per month, on average?
Do you currently use, or have you used PSMA-PET imaging agents?
How would you best describe your practice?
- Academic
- Community
- Private
- Other
How would you describe the size of your practice?
- Large
- Small
- Other
Which of the following describes your practice?
- Outpatient
- Hospital
- Other
How does your PSMA-PET imaging volume compare with 6 months ago?
- Increased volume
- About the same
- Decreased volume
How do you anticipate your PSMA-PET imaging volumes to change over the next 6 months?
- Volume will increase
- Volume will be about the same
- Volume will decrease
How are you currently distributing your usage among the following PSMA-PET imaging agents?
- Pylarify
- Illuccix
- Posluma
- Locametz
- Gozellix
- Other
Please offer insights into the distribution usage in your previous response and explain what factors influenced your choice of the preferred agent or agents.
Do you currently use or plan to use PSMA-PET imaging off-label (for disease monitoring or earlier stage patients)?
How do you expect your usage among the following PSMA-PET imaging agents to be in 1 year?
- Pylarify
- Illuccix
- Posluma
- Locametz
- Gozellix
- Other
Please offer insights into the distribution usage in your previous response and explain what factors influenced your choice of the preferred agent or agents.
How frequently are PSMA PET scans repeated (in terms of months) for patients undergoing PSMA-directed therapy as part of their treatment follow-up, excluding the initial diagnostic scan?
How have recent reimbursement policies influenced your use of PSMA imaging agents?
What do you see as the main difference between Pylarify and Posluma (if any)?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
